Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

1. Siponimod (Mayzent) - secondary progressive multiple sclerosis (SPMS)

Siponimod (Mayzent) - secondary progressive multiple sclerosis (SPMS) 1 Published 12 October 2020 1 SMC2265 siponimod 250 microgram and 2mg film-coated tablets (Mayzent®) Novartis Pharmaceuticals UK Ltd 04 September 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission siponimod (...) (Mayzent®) is accepted for use within NHSScotland. Indication under review: treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. In a randomised, double-blind, placebo-controlled phase III study, siponimod was associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. This advice applies only in the context of an approved NHSScotland Patient

2020 Scottish Medicines Consortium

2. Fampridine - multiple sclerosis (MS)

Fampridine - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/410661/2020 EMEA/H/C/005359 Fampridine Accord (fampridine) An overview of Fampridine Accord (...) and why it is authorised in the EU What is Fampridine Accord and what is it used for? Fampridine Accord is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. MS is a disease in which the immune system (the body’s defences) attacks and damages the covering around the nerves and the nerves themselves in the brain and spinal cord. Fampridine Accord is a ‘generic medicine’. This means that Fampridine Accord contains the same active substance

2020 European Medicines Agency - EPARs

3. Ofatumumab versus Teriflunomide in Multiple Sclerosis. (Full text)

Ofatumumab versus Teriflunomide in Multiple Sclerosis. Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks (...) neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II

2020 NEJM PubMed abstract

4. The Effect of Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients with Multiple Sclerosis: Randomized Controlled Trial

The Effect of Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients with Multiple Sclerosis: Randomized Controlled Trial The Effect of Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients with Multiple Sclerosis: Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) on Chronic Neuropathic Pain in Patients with Multiple Sclerosis: Randomized Controlled Trial , , , Affiliations Expand Affiliations 1 Rehabilitation Department, Royal Melbourne Hospital, Royal Park Campus, Melbourne, Australia. 2 Department of Medicine and Radiology, Integrated Critical Care, University of Melbourne, Melbourne, Australia. 3 Department of Rehabilitation, Nutrition and Sport, Discipline of Physiotherapy, School of Allied Health, La Trobe University, Melbourne, Australia. 4 Department

2020 EvidenceUpdates

5. Fingolimod - relapsing-remitting multiple sclerosis (RRMS)

Fingolimod - relapsing-remitting multiple sclerosis (RRMS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/336317/2020 EMEA/H/C/005191 Fingolimod Accord (fingolimod (...) ) An overview of Fingolimod Accord and why it is authorised in the EU What is Fingolimod Accord and what is it used for? Fingolimod Accord is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (RRMS). ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods with milder or no symptoms (remissions). Fingolimod Accord is used when

2020 European Medicines Agency - EPARs

6. Ozanimod (Zeposia) - relapsing-remitting multiple sclerosis (RRMS)

Ozanimod (Zeposia) - relapsing-remitting multiple sclerosis (RRMS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/171870/2020 EMEA/H/C/004835 Zeposia (ozanimod) An overview (...) of Zeposia and why it is authorised in the EU What is Zeposia and what is it used for? Zeposia is a medicine used to treat adults with relapsing-remitting multiple sclerosis (RRMS), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms (remission). It is used in patients with active disease, which means that patients have relapses or signs of active inflammation on scans. Zeposia contains the active substance ozanimod. How is Zeposia used? Zeposia can only be obtained

2020 European Medicines Agency - EPARs

7. EAN guideline on palliative care of people with severe, progressive multiple sclerosis

EAN guideline on palliative care of people with severe, progressive multiple sclerosis EAN guideline on palliative care of people with severe, progressive multiple sclerosis A. Solari a , A. Giordano a,b , J. Sastre-Garriga c ,S.K€ opke d,e , A. C. Rahn e , I. Kleiter f , K. Aleksovska g , M. A. Battaglia h , J. Bay i , M. Copetti j , J. Drulovic k , L. Kooij l , J. Mens l , E. R. Meza Murillo c , I. Milanov m , R. Milo n,o , T. Pekmezovic p , J. Vosburgh q , E. Silber r , S. Veronese s , F (...) . Patti t , R. Voltz u,v , D. Oliver w and on behalf of the guideline task force , * a Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; b Department of Psychology, University of Turin, Turin, Italy; c Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Universitat Aut onoma de Barcelona, Barcelona, Spain; d Institute of Clinical Nursing Science, University of Cologne, Cologne; e Institute

2020 European Academy of Neurology

8. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT (Full text)

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try (...) Stutters 1 , David MacManus 1 , Ferran Prados 1, 4, 5 , Ian Marshall 2 , Bhavana Solanky 1 , Rebecca S Samson 1 , Frederik Barkhof 1, 4, 6 , Sebastien Ourselin 7 , Marie Braisher 1 , Moira Ross 3 , Gina Cranswick 3 , Sue H Pavitt 8 , Sharmilee Gnanapavan 9 , Gavin Giovannoni 9 , Claudia AM Gandini Wheeler-Kingshott 1, 10 , Clive Hawkins 11 , Basil Sharrack 12 , Roger Bastow 13 , Christopher J Weir 3 , Nigel Stallard 14 , Siddharthan Chandran 2 , Jeremy Chataway 1, 15, * 1 Queen Square Multiple

2020 NIHR HTA programme PubMed abstract

9. Dietary interventions for multiple sclerosis-related outcomes. (Abstract)

Dietary interventions for multiple sclerosis-related outcomes. Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to modulate the immune system to improve MS-related outcomes. There is substantial interest in the ability of dietary interventions to influence MS-related outcomes. This is an update (...) of the Cochrane Review 'Dietary interventions for multiple sclerosis' (Farinotti 2003; Farinotti 2007; Farinotti 2012).To assess the effects of dietary interventions (including dietary plans with recommendations for specific whole foods, macronutrients, and natural health products) compared to placebo or another intervention on health outcomes (including MS-related outcomes and serious adverse events) in people with MS.On 30 May 2019, we searched CENTRAL, MEDLINE, Embase, and Web of Science. We also searched

2020 Cochrane

10. Siponimod (Mayzent) - multiple sclerosis

Siponimod (Mayzent) - multiple sclerosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

11. Ozanimod (Zeposia) - To treat relapsing forms of multiple sclerosis

Ozanimod (Zeposia) - To treat relapsing forms of multiple sclerosis Drug Approval Package: ZEPOSIA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPOSIA Company: Celgene Corporation Application Number: 209899 Approval Date: 03/20/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

12. Immediate and Sustained Effects of Interventions for Changing Physical Activity in People with Multiple Sclerosis: Meta-Analysis of Randomized Controlled Trials. (Abstract)

Immediate and Sustained Effects of Interventions for Changing Physical Activity in People with Multiple Sclerosis: Meta-Analysis of Randomized Controlled Trials. To examine the immediate and sustained effects of interventions for changing physical activity behavior in people with multiple sclerosis (MS), and explore factors that might moderate intervention effects on physical activity behavior (e.g., intervention type and duration, type of physical activity measurement, intensity of theory

2020 Archives of physical medicine and rehabilitation

13. A Systematic Review of the Incidence, Prevalence, Costs, and Activity/Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 (Abstract)

A Systematic Review of the Incidence, Prevalence, Costs, and Activity/Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 To present recent evidence on the prevalence, incidence, costs, activity limitations, and work limitations of common conditions requiring rehabilitation.This was a systematic review. Medline (PubMed), SCOPUS, Web of Science, and the grey (...) literature were searched for relevant articles about amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury. Two investigators independently reviewed articles and selected those for inclusion. Quality grading was performed using the Methodological Evaluation of Observational Research Checklist and Newcastle-Ottawa Quality Assessment Form.110 articles were included. The prevalence of back pain in the past 3 months is 33.9

2020 Archives of physical medicine and rehabilitation

14. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. (Full text)

The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Multiple Sclerosis (MS) displays a heterogeneous clinical onset and progression, which are mostly unpredictable, but demyelination of the central nervous system (CNS) leads to substantial deficits of sensory, motor, autonomic, and neurocognitive functions. Considering all genetic studies on MS, including the advanced genome-wide association studies, the risk linked to HLA alleles remains

2020 Disease markers PubMed abstract

15. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. (Abstract)

Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) can be challenging. To date, an overview of the needs and preferences of patients at each treatment decision-making moment is lacking

2020 Multiple sclerosis and related disorders

16. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. (Full text)

Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. Neurofilament is a biomarker of axonal injury proposed as a useful adjunct in the monitoring of patients with multiple sclerosis (MS). We conducted a systematic review and meta-analysis of case-control studies that have measured neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) of people with MS (pwMS), in order to determine whether, and to what degree

2020 Journal of neurology, neurosurgery, and psychiatry PubMed abstract

17. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. (Full text)

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide

2020 Nature communications PubMed abstract

18. The roles played by TLR4 in the pathogenesis of multiple sclerosis; A systematic review article. (Abstract)

The roles played by TLR4 in the pathogenesis of multiple sclerosis; A systematic review article. Multiple sclerosis (MS) is a world-wide pro-inflammatory based disease, which is prevalent among young individuals. The etiology of the disease and its related complications are yet to be clarified. It has been hypothesized that environmental factors, including pathogen-associated molecular patterns (PAMPs) and the internal factors such as damage-associated molecular patterns (DAMPs), may

2020 Immunology letters

19. Predictive medicine in multiple sclerosis: A systematic review. (Abstract)

Predictive medicine in multiple sclerosis: A systematic review. One of the main challenges in multiple sclerosis (MS) is to predict disease progression based on patient characteristics and therapeutic strategies. We therefore performed a systematic review to critically appraise the composite tools available for this purpose.We performed electronic database searches in MEDLINE, EMBASE, Web of Science and the Cochrane Library. We included studies in English or French that developed

2020 Multiple sclerosis and related disorders

20. Central vein sign for multiple sclerosis: A systematic review and meta-analysis. (Abstract)

Central vein sign for multiple sclerosis: A systematic review and meta-analysis. To systematically review the diagnostic value of the central vein sign (CVS) in multiple sclerosis (MS) and to meta-analyse the proportion of positive lesions for CVS needed to distinguish MS from non-MS mimics.A literature review was performed and a proportion meta-analysis was performed to examine the proportion of the CVS in MS lesions. Studies reporting a threshold of the CVS containing lesions with 100

2020 Clinical Radiology